Answers are grounded in this paper and cite their sources.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the care of patients with metabolic disease due in part to the agonists’ unique combination of effects, including decreasing hyperglycemia and enhancement of satiety [1,2]. GLP-1, a naturally secreted polypeptide, acts on the GLP-1R in multiple organs, including the pancreas, brain, heart, kidney, and stomach [3]. In the gastrointestinal tract, GLP-1 signals are part of the “ileal brake,” increasing gastric emptying time.
No takes yet. Share an insight, caveat, or question.
Kindel et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: